

Erel Joffe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6167962/publications.pdf>

Version: 2024-02-01

81
papers

1,482
citations

471509

17
h-index

361022

35
g-index

82
all docs

82
docs citations

82
times ranked

2990
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	1.4	539
2	Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3109-3117.	1.6	97
3	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	6.2	81
4	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	5.2	64
5	Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e879-e890.	4.6	48
6	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
7	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
8	The value of electrophysiologic study in decision-making regarding the need for pacemaker implantation after TAVI. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 121-130.	1.3	36
9	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
10	The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma. <i>Medicine (United States)</i> , 2016, 95, e2910.	1.0	27
11	A benchmark comparison of deterministic and probabilistic methods for defining manual review datasets in duplicate records reconciliation. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 97-104.	4.4	26
12	Evaluation of a Problem-Specific SBAR Tool to Improve After-Hours Nurse-Physician Phone Communication: A Randomized Trial. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2013, 39, 495-AP6.	0.7	25
13	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	6.2	25
14	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	2.8	21
15	C-reactive protein to distinguish pneumonia from acute decompensated heart failure. <i>Clinical Biochemistry</i> , 2009, 42, 1628-1634.	1.9	20
16	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. <i>Haematologica</i> , 2015, 100, 662-669.	3.5	19
17	C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2009, 20, 518-521.	2.2	18
18	Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study. <i>Blood</i> , 2021, 138, 623-623.	1.4	17

#	ARTICLE	IF	CITATIONS
19	How we treat mature B-cell neoplasms (indolent B-cell lymphomas). Journal of Hematology and Oncology, 2021, 14, 5.	17.0	16
20	Recurrent hospitalizations with moderate to severe hyponatremia in older adults and its associated mortality. European Journal of Internal Medicine, 2014, 25, 624-628.	2.2	15
21	Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?. Blood Advances, 2021, 5, 4185-4197.	5.2	15
22	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research, 2022, 28, 4003-4017.	7.0	15
23	Expert guided natural language processing using one-class classification. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 962-966.	4.4	14
24	Clinical Trials in the Genomic Era. Journal of Clinical Oncology, 2017, 35, 1011-1017.	1.6	14
25	Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma. Bone Marrow Transplantation, 2018, 53, 29-33.	2.4	14
26	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. Blood, 2021, 138, 181-181.	1.4	14
27	Reduced-dose ICE chemotherapy plus rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 1633-1639.	1.3	12
28	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. Leukemia and Lymphoma, 2016, 57, 1382-1388.	1.3	10
29	Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 3382-3390.	5.2	10
30	The relative contribution of urine extravasation to elevation of plasma creatinine levels in acute unilateral ureteral obstruction. Canadian Urological Association Journal, 2015, 9, 428.	0.6	9
31	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. Blood, 2019, 134, 1619-1619.	1.4	9
32	Duplicate patient records—implication for missed laboratory results. AMIA ... Annual Symposium proceedings, 2012, 2012, 1269-75.	0.2	9
33	Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. Leukemia Research, 2014, 38, 484-489.	0.8	8
34	Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 183-183.	1.4	8
35	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances, 2021, 5, 345-351.	5.2	7
36	Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution. Blood, 2019, 134, 22-22.	1.4	7

#	ARTICLE	IF	CITATIONS
37	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. <i>Hematological Oncology</i> , 2017, 35, 734-740.	1.7	6
38	Persistently low lymphocyte counts after <scp>FCR</scp> therapy for chronic lymphocytic leukemia are associated with longer overall survival. <i>Hematological Oncology</i> , 2018, 36, 128-135.	1.7	6
39	Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. <i>European Journal of Haematology</i> , 2018, 101, 502-507.	2.2	6
40	High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2837-2837.	1.4	6
41	Outcomes of secondâ€line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials. <i>European Journal of Haematology</i> , 2018, 101, 399-406.	2.2	5
42	Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 17-18.	1.4	5
43	Collaborative knowledge acquisition for the design of context-aware alert systems. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2012, 19, 988-994.	4.4	4
44	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. <i>Blood</i> , 2016, 128, 2955-2955.	1.4	4
45	Optimized dual threshold entity resolution for electronic health record databases–training set size and active learning. <i>AMIA ... Annual Symposium proceedings</i> , 2013, 2013, 721-30.	0.2	4
46	Errors in after-hours phone consultations: a simulation study. <i>BMJ Quality and Safety</i> , 2014, 23, 398-405.	3.7	3
47	Grade 3A follicular lymphoma can be effectively controlled with very low-dose radiation therapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1500-1503.	1.3	3
48	Outcomes of 210 Patients with Follicular and Marginal Zone Lymphomas Treated with 4 Gy of Radiation Therapy. <i>Blood</i> , 2019, 134, 2827-2827.	1.4	3
49	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
50	Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 46-47.	1.4	3
51	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	1.4	3
52	Effect of vitamin D analogues on acute cardiorenal syndrome: a laboratory rat model. <i>Israel Medical Association Journal</i> , 2013, 15, 693-7.	0.1	3
53	Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia. <i>Anticancer Research</i> , 2015, 35, 2861-6.	1.1	3
54	Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7575-7575.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Is bone marrow examination always necessary to establish the diagnosis of myelodysplastic syndromes? A proposed non-invasive diagnostic model. <i>Leukemia and Lymphoma</i> , 2018, 59, 2227-2232.	1.3	2
56	OUTCOMES OF 180 PATIENTS WITH INDOLENT LYMPHOMAS TREATED WITH VERY LOW DOSE (4 GY) RADIATION THERAPY ALONE. <i>Hematological Oncology</i> , 2019, 37, 222-223.	1.7	2
57	Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT). <i>Blood</i> , 2019, 134, 2826-2826.	1.4	2
58	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population. <i>Blood</i> , 2020, 136, 50-51.	1.4	2
59	Survival Prediction In High Dimensional Datasets – Comparative Evaluation Of Lasso Regularization and Random Survival Forests. <i>Blood</i> , 2013, 122, 1728-1728.	1.4	2
60	Comparison of the Low Toxicity Tecam Conditioning Regimen to BEAM in Patients with Lymphoma Requiring Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3188-3188.	1.4	2
61	Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2904-2904.	1.4	2
62	Kinetics of <sc>preâ€myelodysplastic</sc> syndromes blood values correlate with disease risk and survival. <i>Hematological Oncology</i> , 2020, 38, 782-791.	1.7	1
63	Efficacy and Safety of Frontline Therapy with "FCR" Regimen for Chronic Lymphocytic Leukemia Outside Clinical Trials: Israeli CLL Study Group Experience. <i>Blood</i> , 2014, 124, 5659-5659.	1.4	1
64	Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. <i>Blood</i> , 2021, 138, 3753-3753.	1.4	1
65	Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-38.	1.4	1
66	A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
67	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	6.2	1
68	Gender differences in mortality among statin users aged 80Âyears or more. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2018, 51, 882-888.	1.8	0
69	Radiotherapy is an Effective Definitive Treatment for Limited Stage Grade 3A Follicular Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1016-1017.	0.8	0
70	CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB-ERA. <i>Hematological Oncology</i> , 2019, 37, 251-252.	1.7	0
71	GRADE 3A FOLLICULAR LYMPHOMA CAN BE EFFECTIVELY CONTROLLED WITH VERY LOW DOSE RADIATION THERAPY. <i>Hematological Oncology</i> , 2019, 37, 391-392.	1.7	0
72	INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP-LIKE REGIMENS. <i>Hematological Oncology</i> , 2019, 37, 264-266.	1.7	0

#	ARTICLE	IF	CITATIONS
73	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. <i>Blood</i> , 2014, 124, 3488-3488.	1.4	0
74	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. <i>Blood</i> , 2014, 124, 2132-2132.	1.4	0
75	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2529-2529.	1.4	0
76	The Outcome of CLL Patients According to IGHV Mutational Status: An Israeli Perspective. <i>Blood</i> , 2021, 138, 4686-4686.	1.4	0
77	Quantitative Change in Metabolic Tumor Volume May Assist in Distinguishing between Pseudoprogessors and Responders in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Treated with PD-1 Blockade. <i>Blood</i> , 2021, 138, 1402-1402.	1.4	0
78	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. <i>Blood</i> , 2021, 138, 2513-2513.	1.4	0
79	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. <i>Blood</i> , 2021, 138, 4578-4578.	1.4	0
80	PO-1170 Low-dose radiotherapy for extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. <i>Radiotherapy and Oncology</i> , 2022, 170, S991-S992.	0.6	0
81	Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7560-7560.	1.6	0